INTRODUCTION JANSSEN IN RHEUMATOLOGY

The Janssen Medical Cloud section ‘Janssen in rheumatology’, is intended for physicians working in the field of rheumatology, more
specifically for the disease of Psoriatic Arthritis. As a loyal partner, we offer you, as a physician, useful information and services within this
field.

On our website you will find information about studies, patient materials that you can download, medical education programs, a conference
agenda and so much more.

RHEUMATOLOGY PODCAST

Rheumatology in 2030: a lively conversation between two Benelux key opion leaders in rheumatology.
Check it out and click here below on the episode you want to listen to.

DISCOVER OUR PODCAST >

 

Rheumatology in 2030. A lively conversation between two Benelux key opinion leaders in rheumatology.

Rheumatology in 2030 part 1:

Technical innovations and improvements benefiting both patients and medical specialists

When two distinguished Benelux rheumatologists look ahead to the evolution of their specialty in
the next ten years, their optimism is striking. They emphasize the technical innovations and
improvements that have recently been implemented, which benefit both the patient and the
medical specialist, also on the administrative platform. In a patient-oriented context they will take
advantage of digital means, and they can also communicate and share the best expertise in an
optimal international network. They will also learn a lot more of what’s really happening in the
earliest stages of the disease.

This is only the first piece of the podcast, to listen to the full podcast please click here

 

NEWS

20 November 2020

European Commission has approved TREMFYA® (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate
response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.

16 October 2020

Janssen Receives CHMP Positive Opinion for Expanded Use of TREMFYA® (guselkumab) in the Treatment of Active Psoriatic Arthritis (PsA) in the European Union
(EU).

14 July 2020

TREMFYA® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis.

20 October 2019

Janssen Seeks to Expand Use of TREMFYA® (guselkumab) in the Treatment of Adults with Active Psoriatic Arthritis.

READ MORE

 

Calendar

SPA CONGRESS
 
 

9-11/9/2021

TBD

Michel Delforge and Mohamad Mohty

Webinar

EULAR CONGRESS
 
 

2-5/6/2021

TBD

Michel Delforge and Mohamad Mohty

Webinar

 

CP-208851 - 03-Feb-2021